Search results for "Tassi"

showing 10 items of 997 documents

Photochemically induced, graded cerebral infarction in the mouse by laser irradiation evolution of brain edema

1992

Cerebral infarction was produced in mice by intravenous injection of a photosensitive dye, rose bengal (10 mg/kg), and by focal illumination of the intact skull surface for 3 min with a laser source, operating at 570 nm with power levels of 2, 5, 10, and 20 mW. Location of infarction was made using 2,3,5-triphenyltetrazolium chloride and the time course of edema in the irradiated cerebral hemisphere was evaluated by measuring water, sodium, and potassium content 4, 24, and 72 hr after irradiation. With power levels of 2 and 5 mW, the infarct was restricted to the cortex, whereas with power levels of 10 and 20 mW, it extended to subcortical regions. Increases in water and sodium and decrease…

MaleTime FactorsPhotochemistryPotassiumSodiumInfarctionchemistry.chemical_elementBrain EdemaToxicologyMicechemistry.chemical_compoundCortex (anatomy)EdemaRose bengalAnimalsMedicineIrradiationBrain ChemistryCerebral CortexPharmacologyRose Bengalbusiness.industryCerebral infarctionLasersCerebral InfarctionWater-Electrolyte Balancemedicine.diseaseDisease Models Animalmedicine.anatomical_structurechemistrySpectrophotometryAnesthesiaInjections Intravenousmedicine.symptombusinessBiomedical engineeringJournal of Pharmacological and Toxicological Methods
researchProduct

An early bolus of hypertonic saline hydroxyethyl starch improves long-term outcome after global cerebral ischemia.

2006

Objective: The beneficial effect of hypertonic saline solutions in the emergency treatment of shock and traumatic brain injury is well described. The present study determines effects of a single bolus of hypertonic saline on long-term survival, neurologic function, and neuronal survival 10 days after global cerebral ischemia. In addition, we evaluated the therapeutic window for hypertonic saline treatment (early vs. delayed application). Design: Laboratory experiment. Setting: University laboratory. Subjects: Male Wistar rats weighing 240‐330 g. Interventions: Rats were submitted to temporal global cerebral ischemia using temporary bilateral carotid occlusion combined with hypobaric hypoten…

MaleTime FactorsTraumatic brain injurymedicine.medical_treatmentIschemiaPlasma SubstitutesBlood PressureHydroxyethyl starchCritical Care and Intensive Care MedicineWeight GainBrain IschemiaHydroxyethyl Starch DerivativesBolus (medicine)Intensive caremedicineAnimalsRats WistarSalineNeuronsSaline Solution HypertonicCell Deathbusiness.industrySodiumBrainmedicine.diseaseHypertonic salineRatsCerebral blood flowHematocritAnesthesiaReperfusionPotassiumbusinessmedicine.drugCritical care medicine
researchProduct

Photo-induced chemiluminometric determination of Karbutilate in a continuous-flow Multicommutation assembly

2006

The present paper deals with the chemiluminescent determination of the herbicide Karbutilate on the basis of its previous photodegradation by using a low-pressure Hg lamp as UV source in a continuous-flow multicommutation assembly (a solenoid valves set). The pesticide solution was segmented by a solenoid valve and sequentially alternated with segments of the 0.001 mol l(-1) of NaOH solution, the suitable media for the formation of photo-fragments; then it passes through the photo-reactor and was lead to the flow-cell after being divided in small segments which were sequentially alternated with the oxidizing system; 2 x 10(-5) mol l(-1) of potassium permanganate in 0.2% pyrophosphoric acid.…

MaleUltraviolet RaysClinical BiochemistryAnalytical chemistryPharmaceutical ScienceAnalytical Chemistrylaw.inventionPyrophosphoric acidchemistry.chemical_compoundPotassium PermanganatelawDrug DiscoveryOxidizing agentHumansSodium HydroxideSolenoid valvePhotodegradationSpectroscopyChemiluminescenceDetection limitPhotolysisChromatographyMolecular StructureHerbicidesTemperatureReproducibility of ResultsWaterOxidantsDiphosphatesPotassium permanganatechemistryCalibrationFlow Injection AnalysisLuminescent MeasurementsFemaleCarbamatesOxidation-ReductionQuantitative analysis (chemistry)Journal of Pharmaceutical and Biomedical Analysis
researchProduct

Novel missense mutation in the ATP1A2 gene associated with atypical sporapedic hemiplegic migraine

2019

Hemiplegic migraine (HM) is a rare subtype of migraine with aura in which attacks include transient motor weakness or hemiparesis that can last several days. HM is linked to mutations in three different genes, CACNA1A, ATP1A2 and SCN1A, which encode for ion transporters. The clinical spectrum includes atypical symptoms such as impaired consciousness, epileptic seizures, permanent cerebellar ataxia or mental retardation. We describe a novel mutation found in the ATP1A2 gene in a patient with late-onset HM. His attacks were characterised by motor weakness associated with altered mental status, diplopia and ataxia. He also showed up MRI abnormalities and incomplete response to prophylactic the…

MaleWeaknessPediatricsmedicine.medical_specialtyAtaxiaNeurologyMigraine with AuraMutation MissenseNeuroimagingneuro geneticsDiagnosis Differential03 medical and health sciences0302 clinical medicineRare DiseaseATP1A2medicineHumansMissense mutationgenetic screening / counselling030212 general & internal medicineMigraineAgedNeurologic ExaminationGenetic counsellingCerebellar ataxiabusiness.industryHeadacheGeneral MedicineMagnetic Resonance ImagingMigraine with auraPedigreeHemiparesisNeurologySettore MED/26 - NeurologiaSodium-Potassium-Exchanging ATPasemedicine.symptombusinessheadache (including migraines)030217 neurology & neurosurgery
researchProduct

Xenon Improves Neurologic Outcome and Reduces Secondary Injury Following Trauma in an In Vivo Model of Traumatic Brain Injury*

2014

Objectives: To determine the neuroprotective efficacy of the inert gas xenon following traumatic brain injury and to determine whether application of xenon has a clinically relevant therapeutic time window. Design: Controlled animal study. Setting: University research laboratory. Subjects: Male C57BL/6N mice (n = 196). Interventions: Seventy-five percent xenon, 50% xenon, or 30% xenon, with 25% oxygen (balance nitrogen) treatment following mechanical brain lesion by controlled cortical impact. Measurements and Main Results: Outcome following trauma was measured using 1) functional neurologic outcome score, 2) histological measurement of contusion volume, and 3) analysis of locomotor functio…

MaleXenonINTRACRANIAL-PRESSURE1110 NursingCritical Care and Intensive Care MedicineGAIT ABNORMALITIESXenonGaitIntracranial pressureintegumentary systemBrainGLYCINE SITEINTRACEREBRAL-HEMORRHAGED-ASPARTATE RECEPTORNeuroprotective AgentsTreatment OutcomeAnesthesiahead traumaneuroprotectionLife Sciences & BiomedicinePOTASSIUM CHANNELSLocomotioncirculatory and respiratory physiologyinorganic chemicalsTraumatic brain injurychemistry.chemical_elementNeuroprotection1117 Public Health and Health ServicesHead traumaCritical Care MedicineIn vivoGeneral & Internal MedicineAdministration InhalationmedicineAnimalscardiovascular diseasesIntracerebral hemorrhageScience & Technologybusiness.industry1103 Clinical Sciencesbrain injurymedicine.diseaseCONTROLLED CORTICAL IMPACTCOMPETITIVE-INHIBITIONEmergency & Critical Care MedicineMice Inbred C57BLDisease Models AnimalCOGNITIVE DEFICITSchemistryBrain InjuriesClosed head injurybusinessCLOSED-HEAD INJURYinert gasesCritical Care Medicine
researchProduct

Characterization of a Ryanodine Receptor inPeriplaneta Americana

1997

Specific binding sites for the alkaloid ryanodine were characterized in membrane preparations from sarcoplasmatic reticulum of Periplaneta americana skeletal muscle. Binding of [3H]ryanodine was optimal at pH 8 and at CaCl2 concentration of about 300 mumol l-1. The Ca-chelating agents EGTA (100 mumol l-1) and EDTA (100 mumol l-1) abolished 95% and 90% of the [3H]ryanodine binding respectively. Preincubation with Ca2+ (100 mumol l-1) restored the ryanodine binding in presence of up to 300 mumol l-1 EGTA. Radioligand binding experiments showed one class of high affinity binding sites for ryanodine. Determination of rate constants revealed 7.05 x 10(6) l mol-1 min-1 for associating and 3.77 x …

Maleanimal structuresMuscle ProteinsBiochemistrymedicineAnimalsPeriplanetaheterocyclic compoundsBinding siteEgtazic AcidMolecular BiologyEdetic AcidbiologyRyanodineRyanodine receptorChemistryMusclesAlkaloidSodiumfungiSkeletal muscleRyanodine Receptor Calcium Release ChannelCell BiologyHydrogen-Ion Concentrationbiology.organism_classificationmedicine.anatomical_structureBiochemistryPotassiumCalciumCalmodulin-Binding ProteinsFemaleCalcium ChannelsReticulumPeriplanetaJournal of Receptors and Signal Transduction
researchProduct

Inhibitory effects of N-valproyl-L-tryptophan on high potassium, low calcium and low magnesium-induced CA1 hippocampal epileptiform bursting activity…

2012

N-valproyl-l-tryptophan (VPA-Tryp), new antiepileptic drug, was tested on CA1 hippocampal epileptiform bursting activity obtained by increasing potassium and lowering calcium and magnesium concentrations in the fluid perfusing rat brain slices. Each slice was treated with a single concentration (0.2, 0.5, 1 or 2 mM) of Valproate (VPA) or VPA-Tryp. Both burst duration and interburst frequency during and after treatment were off-line compared with baseline values. For both parameters, the latency and the length of statistically significant response periods as well as the magnitude of drug-induced responses were calculated. VPA-Tryp evoked fewer and weaker early excitatory effects than VPA on …

Maleantiepileptic drug valproic acidPotassiumchemistry.chemical_elementAction PotentialsCalciumHippocampal formationPharmacologyIn Vitro TechniquesInhibitory postsynaptic potentialSettore BIO/09 - Fisiologiaamino-acidic derivativeBurstingmedicineReaction Timehippocampal epilepsyAnimalsDrug InteractionsMagnesiumRats WistarCA1 Region HippocampalBiological PsychiatryValproic AcidAnalysis of VarianceDose-Response Relationship DrugMagnesiumDipeptidesElectric StimulationRatsPsychiatry and Mental healthNeurologychemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoExcitatory postsynaptic potentialPotassiuminterictal burstslipids (amino acids peptides and proteins)AnticonvulsantsNeurology (clinical)medicine.drugJournal of neural transmission (Vienna, Austria : 1996)
researchProduct

CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction

2020

BACKGROUND: The optimal diuretic treatment strategy for patients with acute heart failure and renal dysfunction remains unclear. Plasma carbohydrate antigen 125 (CA125) is a surrogate of fluid overload and a potentially valuable tool for guiding decongestion therapy. The aim of this study was to determine if a CA125-guided diuretic strategy is superior to usual care in terms of short-term renal function in patients with acute heart failure and renal dysfunction at presentation. METHODS: This multicenter, open-label study randomized 160 patients with acute heart failure and renal dysfunction into 2 groups (1:1). Loop diuretics doses were established according to CA125 levels in the CA125-gui…

Maleendocrine system diseasesPREDICTIONmedicine.medical_treatmentUrine030204 cardiovascular system & hematologyKidney Function TestsCONGESTIONBiomarker guided-therapy0302 clinical medicineSodium Potassium Chloride Symporter InhibitorsFurosemideNatriuretic peptideMedicineRenal Insufficiency030212 general & internal medicinePrecision MedicineANTIGEN CARBOHYDRATE 125Aged 80 and overFurosemideGeneral MedicineDiuretic treatmentEUROPEAN-SOCIETYClinical trialFemaleTRIALmedicine.drugmedicine.medical_specialtyRenal failureSTRATEGIESmedicine.drug_classUrologyRenal function03 medical and health sciencesHumansIn patientAgedHeart FailureSERUM CREATININENATRIURETIC PEPTIDEbusiness.industryMORTALITYMembrane ProteinsAcute heart failuremedicine.diseaseClinical trialCarbohydrate antigen 125CA-125 AntigenHeart failureDiuretic treatmentDiureticbusinessCARDIORENAL SYNDROME
researchProduct

Increased contraction to noradrenaline by vasopressin in human renal arteries

2002

Arginine vasopressin (AVP) not only acts directly on blood vessels through vasopressin V1 receptor stimulation but also may modulate adrenergic-mediated responses in animal experiments. The aim of the present study was to assess whether subpressor concentrations of AVP could contribute to an abnormal adrenergic contractile response of human renal arteries.Renal artery rings were obtained from 27 patients undergoing nephrectomy. The rings were suspended in organ bath chambers for isometric recording of tension.AVP (10(-10) mol/l) and the vasopressin V1 receptor agonist [Phe2, Orn8]-vasotocin (10(-10) mol/l) produced a leftward shift of the concentration-response curve to noradrenaline (half-…

Maleendocrine systemVasopressinmedicine.medical_specialtyContraction (grammar)NifedipineArgininePhysiologyNeuropeptideStimulationPotassium ChlorideNorepinephrineRenal ArteryInternal medicineInternal MedicinemedicineHumansVasoconstrictor AgentsEnzyme InhibitorsAgedVasopressin receptoromega-N-MethylarginineDose-Response Relationship Drugurogenital systembusiness.industryMiddle AgedCalcium Channel BlockersArginine VasopressinEndocrinologymedicine.anatomical_structureVasoconstrictionCirculatory systemFemaleCardiology and Cardiovascular MedicinebusinessAntidiuretic Hormone Receptor Antagonistshormones hormone substitutes and hormone antagonistsBlood vesselJournal of Hypertension
researchProduct

SODIUM FRACTION EXCRETION RATE IN NOCTURNAL ENURESIS CORRELATES WITH NOCTURNAL POLYURIA AND OSMOLALITY

2004

Abstract: Purpose: We verify the sodium fraction excretion rate (FE Na) and potassium fraction excretion WE K) rates in monosymptomatic nocturnal enuresis. We also correlate FE Na and FE K to urinary osmolality, nocturnal polyuria and vasopressin in the same population. Materials and Methods: A total of 438 children 6 to 15 years old (mean age 9.7) presenting with monosymptomatic nocturnal enuresis were recruited from different centers. Inclusion criteria were 3 or greater wet nights a week, no daytime incontinence and no treatment in the previous 2 months. Exclusion criteria were cardiopathy, endocrinopathy, psychiatric problems and urinary tract abnormalities. Micturition chart, diurnal (…

Maleenuresis polyuria vasopressin urinary incontinencemedicine.medical_specialtyAdolescentVasopressinsUrologyPopulationDiuresisUrinary incontinenceNocturnalExcretionPolyuriaEnuresisInternal medicineHumansMedicineChildeducationDesmopressineducation.field_of_studyPolyuriabusiness.industryOsmolar ConcentrationSodiumEnuresisEndocrinologyPotassiumFemalemedicine.symptombusinessmedicine.drugJournal of Urology
researchProduct